Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if lenalidomide (Revlimid®)reduces proinflammatory
cytokines including TNF-alpha and may actually alter the clinical course of autism for some
children.